Clinical / PharmaceuticalAlso known as: AT-1001, Larazotide acetate, zonulin antagonist
Larazotide
First-in-class tight junction regulator — zonulin receptor antagonist in Phase 3 for celiac disease. Reduces intestinal permeability (leaky gut) without immunosuppression.
Half-Life
~4-6 hours (estimated)
Dose Range
0.5-1 mg 3× daily (oral)
Frequency
3× daily (oral, before meals)
Vial Sizes
N/A (oral)
Mechanism of Action
Octapeptide that blocks zonulin-mediated opening of intestinal tight junctions. Zonulin (pre-haptoglobin-2) is released in response to gluten, triggering paracellular permeability. Larazotide prevents tight junction protein ZO-1 displacement, maintaining barrier integrity.
Source: PMID: 32784092 (Phase 3)
Dosing Protocol
| Typical Dose | 0.5-1 mg 3× daily (oral) |
| Frequency | 3× daily (oral, before meals) |
| Half-Life | ~4-6 hours (estimated) |
Dosing Quick Reference
Larazotide— Dosing Guide
Dose Range
0.5-1 mg 3× daily (oral)
Half-Life
~4-6 hours (estimated)
Frequency
3× daily (oral, before meals)
Route
Oral
Clinical / Pharmaceuticalcalcmypeptide.com
Looking for a trusted source? See our recommended suppliers →
Independently tested · COA-verified · Save 10% with our exclusive code